189 related articles for article (PubMed ID: 21534534)
1. Organometallic ruthenium(II) arene compounds with antiangiogenic activity.
Nowak-Sliwinska P; van Beijnum JR; Casini A; Nazarov AA; Wagnieres G; van den Bergh H; Dyson PJ; Griffioen AW
J Med Chem; 2011 Jun; 54(11):3895-902. PubMed ID: 21534534
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
[TBL] [Abstract][Full Text] [Related]
3. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains.
Nowak-Sliwinska P; Clavel CM; Păunescu E; te Winkel MT; Griffioen AW; Dyson PJ
Mol Pharm; 2015 Aug; 12(8):3089-96. PubMed ID: 26158308
[TBL] [Abstract][Full Text] [Related]
5. Combination of ruthenium(II)-arene complex [Ru(η
Berndsen RH; Weiss A; Abdul UK; Wong TJ; Meraldi P; Griffioen AW; Dyson PJ; Nowak-Sliwinska P
Sci Rep; 2017 Feb; 7():43005. PubMed ID: 28223694
[TBL] [Abstract][Full Text] [Related]
6. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
[TBL] [Abstract][Full Text] [Related]
7. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
[TBL] [Abstract][Full Text] [Related]
8. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization, and in vitro cytotoxicity of some gold(I) and trans platinum(II) thionate complexes containing water-soluble PTA and DAPTA ligands. X-ray crystal structures of [Au(SC4H3N2)(PTA)], trans-[Pt(SC4H3N2)2(PTA)2], trans-[Pt(SC5H4N)2(PTA)2], and trans-[Pt(SC5H4N)2(DAPTA)2].
Miranda S; Vergara E; Mohr F; de Vos D; Cerrada E; Mendía A; Laguna M
Inorg Chem; 2008 Jul; 47(13):5641-8. PubMed ID: 18447334
[TBL] [Abstract][Full Text] [Related]
11. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
12. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
Ratanaphan A; Temboot P; Dyson PJ
Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
[TBL] [Abstract][Full Text] [Related]
13. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
[TBL] [Abstract][Full Text] [Related]
15. DNA structural distortions induced by ruthenium-arene anticancer compounds.
Gossens C; Tavernelli I; Rothlisberger U
J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium(II)-arene complexes with functionalized pyridines: synthesis, characterization and cytotoxic activity.
Grgurić-Sipka S; Ivanović I; Rakić G; Todorović N; Gligorijević N; Radulović S; Arion VB; Keppler BK; Tesić ZLj
Eur J Med Chem; 2010 Mar; 45(3):1051-8. PubMed ID: 20053483
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex.
Clavel CM; Păunescu E; Nowak-Sliwinska P; Griffioen AW; Scopelliti R; Dyson PJ
J Med Chem; 2014 Apr; 57(8):3546-58. PubMed ID: 24669938
[TBL] [Abstract][Full Text] [Related]
18. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.
Mandal P; Kundu BK; Vyas K; Sabu V; Helen A; Dhankhar SS; Nagaraja CM; Bhattacherjee D; Bhabak KP; Mukhopadhyay S
Dalton Trans; 2018 Jan; 47(2):517-527. PubMed ID: 29235601
[TBL] [Abstract][Full Text] [Related]
20. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
